Patents by Inventor Iain Simpson

Iain Simpson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arginase inhibitors and methods of use thereof
    Patent number: 11912727
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Grant
    Filed: July 10, 2023
    Date of Patent: February 27, 2024
    Assignee: AstraZeneca AB
    Inventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
  • Arginase Inhibitors and Methods of Use Thereof
    Publication number: 20230365599
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 16, 2023
    Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
  • Arginase Inhibitors and Methods of Use Thereof
    Publication number: 20230122859
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Application
    Filed: July 15, 2022
    Publication date: April 20, 2023
    Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
  • Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof
    Publication number: 20230110165
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Application
    Filed: October 7, 2022
    Publication date: April 13, 2023
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Imidazo[4,5-C]pyridine derived SSAO inhibitors
    Patent number: 11530208
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R1, W, V, and R3 are as defined in claim 1.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 20, 2022
    Assignee: PROXIMAGEN, LLC
    Inventors: Lee Patient, Iain Simpson, Edward Savory
  • Substituted imidazo[4,5-c]pyridine compounds and compositions thereof
    Patent number: 11512082
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 29, 2022
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • CXCR4 Receptor Antagonists
    Publication number: 20220348577
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: March 2, 2021
    Publication date: November 3, 2022
    Inventors: Giles Brown, Michael Higginbottom, Alison Stewart, Lee Patient, Allison Carley, Iain Simpson, Edward Daniel Savory, Kathryn Oliver, Andrew Graham Cole
  • ARGINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220267356
    Abstract: Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cancer or a respiratory inflammatory disease using the same: wherein R1 is selected from hydrogen, —CH3 and —(C?O)CH(R1a)NH2; R1a is C1-C4 alkyl; Y is —(CH2)n— or —(C?O)—; n is an integer selected from 1 and 2; R2 is selected from hydrogen, —CH3 and —(C?X)R4 and R3 is hydrogen or —CH3; or R2 and R3, together with the nitrogen to which they are attached, are linked to form a 6-membered heterocyclic ring; X is NH or O; R4 is —CH3 or —[CH(R4a)]mNH2; m is an integer selected from 0 or 1; and R4a is hydrogen or C1-C6 alkyl.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 25, 2022
    Inventors: Scott Nathan MLYNARSKI, Jason SHIELDS, Sameer KAWATKAR, Qing YE, Haixia WANG, Xiaolan ZHENG, Ray FINLAY, Iain SIMPSON
  • Arginase inhibitors and methods of use thereof
    Patent number: 11420984
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: August 23, 2022
    Assignee: AstraZeneca AB
    Inventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
  • FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS
    Publication number: 20220204527
    Abstract: The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 30, 2022
    Inventors: Jason Grant KETTLE, Iain SIMPSON, Christopher PHILLIPS, Scott BOYD, Oliver Ross STEWARD, Michael Steven BODNARCHUK, Doyle Joseph CASSAR, Kurt Gordon PIKE
  • ARGINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220106335
    Abstract: Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase; wherein R is —H or —C(O)CH(R1a)NHR1b; and R1a is selected from —H, —(C1-C4) alkyl and CH2OR1c; R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1c is H or —CH3.
    Type: Application
    Filed: February 7, 2020
    Publication date: April 7, 2022
    Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON
  • CXCR4 receptor antagonists
    Patent number: 10995091
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 4, 2021
    Assignee: Proximagen LLC
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
    Patent number: 10968223
    Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: April 6, 2021
    Assignee: Proximagen, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • Arginase Inhibitors and Methods of Use Thereof
    Publication number: 20210002305
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Application
    Filed: February 15, 2019
    Publication date: January 7, 2021
    Inventors: Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20200347059
    Abstract: A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia)
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
  • Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
    Patent number: 10766897
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 8, 2020
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory
  • COMPOUNDS
    Publication number: 20200262835
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R1, and R3 are as defined herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: August 20, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Edward SAVORY, Iain SIMPSON
  • Compounds
    Patent number: 10590125
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: March 17, 2020
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
    Publication number: 20200002335
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Application
    Filed: August 16, 2019
    Publication date: January 2, 2020
    Applicant: PROXIMAGEN, LLC
    Inventors: Max ESPENSEN, Lee PATIENT, David EVANS, Iain SIMPSON, Edward SAVORY
  • Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
    Patent number: 10428066
    Abstract: The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 1, 2019
    Assignee: PROXIMAGEN, LLC
    Inventors: Max Espensen, Lee Patient, David Evans, Iain Simpson, Edward Savory